10x Genomics, Inc. (NASDAQ: TXG) saw its stock surge 5.47% in after-hours trading on Thursday, following the release of its impressive second-quarter 2025 financial results, the announcement of a strategic acquisition, and positive future guidance.
The biotechnology company significantly outperformed analyst expectations, reporting quarterly earnings of $0.28 per share, a dramatic turnaround from the $(0.32) per share loss reported in the same period last year. Revenue also exceeded expectations, coming in at $172.9 million, beating the analyst consensus estimate of $139.4 million by 24.02%. This strong performance marks a 12.93% increase in sales compared to the previous year. The company's gross margin improved to 72%, driven by higher license and royalty revenue.
Adding to the positive sentiment, 10x Genomics announced plans to acquire Scale Biosciences, a move expected to strengthen its single-cell analysis capabilities and potentially expand its market presence. Furthermore, the company provided an optimistic outlook for the third quarter of 2025, projecting revenue in the range of $140 million to $144 million. This combination of strong current performance, strategic expansion, and positive future guidance likely contributed to the stock's after-hours rally, despite ongoing challenges in the funding environment and market uncertainties.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.